Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...
Amgen’s famously voracious legal team is living up to its reputation once again, this time with a surprise challenge on the patents surrounding Alexion’s rare diseases blockbuster, Soliris.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback